Development of activity standard for 90Y microspheres

Li, Mo; Avci, B.; James, D.; Simpson, B.R.S.; Wyngaardt, W.M. van; Cessna, Jeffrey T.; Baldock, Clive

doi:10.1016/j.apradiso.2005.02.002

Cited by 24 publications

(25 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Variations in container materials and source position within the dose calibrator can affect the local calibration standard. 50,53,54 In the absence of a well defined local calibration procedure, variations in activity measurements on the order of 10% can occur. 55,56 Given no availability of an Accredited Dosimetry Calibration Laboratory (ADCL) traceable activity standard for microspheres, a fixed geometrical technique for reference activity measurements should be established at the local clinic level and used consistently.…”

Section: Vd Vendor To Local Clinicmentioning

confidence: 99%

“…Mo et al 50 detailed another calibration of the activity of SIR-Spheres V R independent of the manufacturer and it is briefly described. For the production of SIR-Spheres V R , it was necessary to relate measurements made during production to Australian national standards for measurement of 90 Y. Calibration factors were determined for four different ionization chamber models using an intermediate geometry of the production and the final geometry.…”

Section: Vb Sir-spheresmentioning

confidence: 99%

See 1 more Smart Citation

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰Y microsphere brachytherapy in the treatment of hepatic malignancies

Dezarn¹,

et al. 2011

View full text Add to dashboard Cite

Yttrium-90 microsphere brachytherapy of the liver exploits the distinctive features of the liver anatomy to treat liver malignancies with beta radiation and is gaining more wide spread clinical use. This report provides a general overview of microsphere liver brachytherapy and assists the treatment team in creating local treatment practices to provide safe and efficient patient treatment. Suggestions for future improvements are incorporated with the basic rationale for the therapy and currently used procedures. Imaging modalities utilized and their respective quality assurance are discussed. General as well as vendor specific delivery procedures are reviewed. The current dosimetry models are reviewed and suggestions for dosimetry advancement are made. Beta activity standards are reviewed and vendor implementation strategies are discussed. Radioactive material licensing and radiation safety are discussed given the unique requirements of microsphere brachytherapy. A general, team-based quality assurance program is reviewed to provide guidance for the creation of the local procedures. Finally, recommendations are given on how to deliver the current state of the art treatments and directions for future improvements in the therapy.

show abstract

Section: Vd Vendor To Local Clinicmentioning

confidence: 99%

Section: Vb Sir-spheresmentioning

confidence: 99%

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰Y microsphere brachytherapy in the treatment of hepatic malignancies

Dezarn¹,

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Le protocole de dissolution mis au point au laboratoire permet de dissoudre la totalité des microsphères par ajout direct des différents réactifs chimiques dans le flacon d'origine. Une procé-dure de dissolution des microsphères SIR-Spheres avait déjà été adoptée par Mo et al [6] pour l'étalonnage des chambres d'ionisation à l'ANSTO (Australie) mais pour des raisons commerciales, le protocole n'a pas été publié. Par ailleurs, les auteurs indiquent que la procédure de dissolution utilisée ne permettait pas de dissoudre la totalité des microsphères dans le volume total de solution (5 mL) dans le flacon d'origine.…”

Section: Contexte Et Objectif De L'étudeunclassified

Réalisation d’une référence nationale pour les microsphères de 90Y utilisées en radiothérapie interne sélective

Bobin¹,

Thiam²,

Lourenço³

et al. 2017

R. franç. métrol.

View full text Add to dashboard Cite

RésuméLa radiothérapie interne vectorisée consiste à injecter un agent thé-rapeutique d'activité connue afin de délivrer une dose interne élevée à la tumeur, tout en préservant les tissus sains. Le projet Euramet/EMRP MetroMRT « Metrology for Molecular Radiotherapy » avait pour but de faire collaborer des laboratoires européens de métrologie et des services de médecine nucléaire afin de leur apporter une expertise métrologique dans le domaine de la radiothérapie interne vectorisée. En particulier, un des objectifs du projet dans lequel le LNE-LNHB était impliqué était d'établir une référence nationale pour des microsphères de résine marquées avec 90 Y (SIR-Spheres). Cet agent thérapeutique produit par la société Sirtex (Sydney, Australie) pour la radiothérapie interne sélec-tive est destiné au traitement des tumeurs non opérables du foie par radioembolisation. La mesure primaire d'activité des microsphères de 90 Y a été effectuée après leur dissolution complète dans le flacon d'origine du fabricant. Deux types de mesures par la méthode RCTD ont été utilisés, l'un repose sur la scintillation liquide, l'autre sur l'émission Cherenkov. Une méthode de dissolution originale a également été mise au point au LNE-LNHB afin d'optimiser l'homogénéité de la solution radioactive destinée aux mesures. Une description de cette méthode est détaillée dans cet article. L'étalonnage des chambres d'ionisation du LNE-LNHB pour le transfert de la référence des microsphères de 90 Y vers les utilisateurs est également traité. Une étude a été réalisée pour déterminer l'influence de l'inhomogénéité de la géométrie des flacons sur l'incertitude associée au coefficient d'étalonnage dans le cas des émetteurs β − purs tels que 90 Y. La réalisation d'une référence nationale avait également pour but de réduire l'incertitude relative (10 %) donnée par la société Sirtex sur l'activité (3 GBq) des microsphères SIR-Spheres qu'elle produit. MOTS CLÉS : MÉTROLOGIE DE L'ACTIVITÉ, MICROSPHÈRES DE Y-90, DISSOLUTION DE RÉSINE ÉCHANGEUSE D'IONS, MÉTHODE RCTD, SCINTILLATION LIQUIDE, ÉMISSION CHERENKOV, CHAMBRE D'IONISATION, RADIOTHÉRAPIE INTERNE. Abstract Molecular radiotherapy consists in the injection of a therapeutic agent with known activity in order to deliver a high-dose radiation directly to the tumors while sparing healthy tissues. The Euramet/EMRP project MetroMRT "Metrology for Molecular Radiotherapy" was intended to bring together national metrology laboratories and nuclear medicine services in order to give them metrological support in the field of molecular radiotherapy. In particular, LNE-LNHB was involved in the project for the standardization of 90 Y-labelled resin microspheres (SIR-Spheres

show abstract

“…Previous work by Mo et al [3] described the development of an activity standard for resin microspheres. In their work the authors first performed primary and secondary standardizations on a 90 Y solution.…”

Section: Measurement Of Administered Activitymentioning

confidence: 99%

Metrological Issues in Molecular Radiotherapy

D’Arienzo

Capogni

Smyth

et al. 2014

EPJ Web of Conferences

View full text Add to dashboard Cite

Abstract. The therapeutic effect from molecular radiation therapy (MRT), on both tumour and normal tissue, is determined by the radiation absorbed dose. Recent research indicates that as a consequence of biological variation across patients the absorbed dose can vary, for the same administered activity, by as much as two orders of magnitude. The international collaborative EURAMET-EMRP project ಯMetrology for molecular radiotherapy (MetroMRT)ರ is addressing this problem. The overall aim of the project is to develop methods of calibrating and verifying clinical dosimetry in MRT. In the present paper an overview of the metrological issues in molecular radiotherapy is provided. Introducing the problem of molecular radiation therapyMolecular radiation therapy (MRT), also known as targeted radionuclide therapy, is a unique form of radiotherapy where a high radiation dose is delivered internally, ideally to a specific target. The therapeutic agent may be administrated in several ways: ingestion, intravenous infusion, injection to a body cavity or pathological space (locoregional therapy) or direct injection into a solid tumour.Molecular radiotherapy is routinely prescribed on the basis of administered activity of the therapeutic agent. However, uptake and retention differ from patient to patient and therefore the individual dose to the target can vary between patients given the same administered activity. Recent research indicates the range of variation can be up to two orders of magnitude, which is particularly alarming from the point of view of radiation protection [1,2]. At the low extreme, the patient might gain negligible therapeutic benefit. At the high extreme, the patient might receive more radiation than is needed to treat the tumour. Both cases technically constitute maladministrations.Recent research and new technology developments have permitted estimates of radiation dose in individual patients to target tissues and critical normal tissues at risk to be obtained. However, there has been almost no adoption of these methodologies in routine clinical MRT practice. The reasons are many, but, mainly because the methodology is difficult, there is no standardization of procedures, and there is no objective means of predicting the effect of individual patient dosimetry on treatment outcomes.In fact, when compared with conventional external beam radiotherapy, in which individual patient dosimetry is mandatory and strictly controlled according to agreed protocols, there is full traceability to primary standards, and there are even legal requirements for accuracy (within 5 % of a reference value), it is clear that MRT is urgently in need of metrological support in order to bring dosimetry practice to an acceptable and comparable standard.The new international collaborative EURAMET-EMRP project ಯMetrology for molecular radiotherapyರ (MetroMRT) is addressing this problem. The project is developing the background metrology to support routine individual MRT patient dosimetry, and together with a programme of disseminatio...

show abstract

Development of activity standard for 90Y microspheres

Cited by 24 publications

References 10 publications

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰Y microsphere brachytherapy in the treatment of hepatic malignancies

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰Y microsphere brachytherapy in the treatment of hepatic malignancies

Réalisation d’une référence nationale pour les microsphères de 90Y utilisées en radiothérapie interne sélective

Metrological Issues in Molecular Radiotherapy

Contact Info

Product

Resources

About

Development of activity standard for 90Y microspheres

Cited by 24 publications

References 10 publications

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for 90Y microsphere brachytherapy in the treatment of hepatic malignancies

Réalisation d’une référence nationale pour les microsphères de 90Y utilisées en radiothérapie interne sélective

Metrological Issues in Molecular Radiotherapy

Contact Info

Product

Resources

About

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰Y microsphere brachytherapy in the treatment of hepatic malignancies

Recommendations of the American Association of Physicists in Medicine on dosimetry, imaging, and quality assurance procedures for ⁹⁰Y microsphere brachytherapy in the treatment of hepatic malignancies